TTX-080
Based on 1 Customer Validation
TTX-080 is a humanized monoclonal antagonistic antibody targeting human leukocyte antigen G (HLA-G). TTX-080 exerts anti-tumor activity by relieving HLA-G-mediated immune suppression. TTX-080 is promising for research of solid tumors such as metastatic colorectal cancer (mCRC) and head and neck squamous cell carcinoma (mHNSCC).
For research use only. We do not sell to patients.
- Purity : 96.52%
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
HLA-G
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Application
ELISA, FACS, Functional assay
Product Details
-
Accession P17693
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG1 kappa
-
Recommend Isotype Controls
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Purity
96.52%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Shipping
Shipping with dry ice.
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)